Showing 1281-1290 of 3001 results for "".
- Women with Multiple Sclerosis May Be Missing Breast Cancer Screeningshttps://practicalneurology.com/news/women-with-multiple-sclerosis-may-be-missing-breast-cancer-screenings/2469895/In a study published in Neurology, women with multiple sclerosis (MS) were less likely to have breast cancer detected through screenings than women without MS. Women with MS were also more likely to have colorectal cancers detected early with screenings compared with women without MS. Th
- FDA Approves Diroximel Fumarate—A Second Generation Fumarate With Fewer Side Effects—for Treatment of Multiple Sclerosishttps://practicalneurology.com/news/fda-approves-diroximel-fumaratea-second-generation-fumarte-with-fewer-side-effectsfor-treatment-of-multiple-sclerosis/2469063/The Food and Drug Administration has approved diroximel fumarate (Vumerity; Biogen, Cambridge, MA and Alkermes, Dublin, Ireland) for the treatment of multiple sclerosis (MS) including clinically isolated syndrome (CIS), relapsing remitting MS (RRMS), and active secondary progressive MS (SPMS). &n
- Siponimod Approved by FDA for Treatment of Relapsing-Remitting and Secondary-Progressive Multiple Sclerosishttps://practicalneurology.com/news/siponimod-approved-by-fda-for-treatment-of-relapsing-remitting-and-secondary-progressive-multiple-sclerosis/2468792/The first drug to treat 3 phases of multiple sclerosis (MS), secondary-progressive MS (SPMS), relapsing-remitting MS (RRMS), and clinically isolated syndrome (CIS), has been approved by the Food and Drug Administration (FDA). Siponimod (Mayzent; Novartis, East Hanover, NJ) is an oral agent a
- Long-Term Data from Real-World CLARENCE Study Show Stable Disability Outcomes in Patients with Highly Active Relapsing MS Treated with Mavencladhttps://practicalneurology.com/news/long-term-data-from-real-world-clarence-study-show-stable-disability-outcomes-in-patients-with-highly-active-relapsing-ms-treated-with-mavenclad/2470330/After 5 years of follow-up, people with highly active relapsing multiple sclerosis (RMS) treated with Mavenclad (cladribine tablets; Merck, Darmstadt, Germany) showed high rates of treatment persistence and low rates of switching to other disease-modifying therapies (DMTs). These results from an
- Short-Term Stress Management Protocol Improves Objective and Self-Reported Measures of Stress and Mood in Patients with MS According to New Researchhttps://practicalneurology.com/news/short-term-stress-management-protocol-improves-objective-and-self-reported-measures-of-stress-and-mood-in-patients-with-ms-according-to-new-research/2470202/Research presented at the 2023 Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC) suggests that participating in a program providing short-term psychotherapy in stress management techniques improves mood
- T-Cell Therapy Targeting Epstein-Barr Virus Provided Sustained Disability Improvement for Progressive MS in Phase 1a Clinical Trialhttps://practicalneurology.com/news/t-cell-therapy-targeting-epstein-barr-virus-provided-sustained-disability-improvement-for-progressive-ms-in-phase-1a-clinical-trial/2469377/An Epstein-Barr virus (EBV)-targeting, off-the-shelf allogeneic T-Cell therapy (ATA188; Atara, South San Francisco, CA) was well tolerated and showed signs of efficacy measured as sustained disability improvement (SDI) in participants with progressive multiple sclerosis (PMS). In this Phase 1a 12
- In Memoriam: June Halper, MSN, APN-C, FAAN, MSCNhttps://practicalneurology.com/news/in-memoriam-june-halper-msn-apn-c-faan-mscn/2470537/June Halper, MSN, ASPN-C, FAAN, MSCN passed away on July 24, 2024, at age 86. Ms. Halper was a founding member of the Consortium of Multiple Sclerosis Centers (CMSC) and served as the organization’s President from 1995 to 1997 and as its Executive Director/CEO from 1992 until her death. Ms.
- Award Recipients Recognized at 2025 International MDS Conferencehttps://practicalneurology.com/news/award-recipients-recognized-at-the-2025-international-congress-of-parkinsons-disease-and-movement-disorders/2483939/The International Parkinson’s Disease and Movement Disorders Society (MDS) has recognized recipients of the 2025 MDS Awards. The awards honor professionals in the field who are elevating care for movement disorders through their contributions to research, scholarship, and clinical work. The award
- Nanocrystalline Gold Provides Functional Improvements for Relapsing Multiple Sclerosishttps://practicalneurology.com/news/nanocrystalline-gold-provides-functional-improvements-for-relapsing-multiple-sclerosis/2470004/In the VISIONARY-MS clinical trial (NCT03536559), participants with relapsing multiple sclerosis (MS) and optic neuritis (ON) treated with nanocrystalline gold (CNM-Au8; Clene Inc, Salt Lake City,
- Gastrointestinal Tolerability of Diroximel Fumarate May Shorten Time to Reach Optimal Dosehttps://practicalneurology.com/news/gastrointestinal-tolerability-of-diroximel-fumarate-may-shorten-time-to-reach-optimal-dose/2469719/In the phase 3 EVOLVE-MS-2 study (NCT03093324), individuals with relapsing multiple sclerosis (MS) treated with diroximel fumarate (Vumerity; Biogen, Cambridge, MA) (n=253) had improved gastrointestinal (GI) tolerability compared with